Korean Circulation Journal

  • 제46권5호
  • /
  • Pages.719-726
  • /
  • 2016
  • /
  • 1738-5520(pISSN)
  • /
  • 1738-5555(eISSN)
대한심장학회 (The Korean Society of Cardiology)
권호 표지
DOI QR코드

DOI QR Code

Retrospective Multicenter Study of Respiratory Syncytial Virus Prophylaxis in Korean Children with Congenital Heart Diseases

  • 투고 : 2015.09.21
  • 심사 : 2015.11.02
  • 발행 : 2016.09.30
⟨ 이전 논문 다음 논문 ⟩

초록

Background and Objectives: We conducted a review of current data on respiratory syncytial virus (RSV) prophylaxis with palivizumab, in Korean children with congenital heart diseases (CHD). In 2009, the Korean guideline for RSV prophylaxis had established up to five shots monthly per RSV season, only for children <1 year of age with hemodynamic significance CHD (HS-CHD). Subjects and Methods: During the RSV seasons in 2009-2015, we performed a retrospective review of data for 466 infants with CHD, examined at six centers in Korea. Results: Infants received an average of $3.7{\pm}1.9$ (range, 1-10) injections during the RSV season. Fifty-seven HS-CHD patients (12.2%) were hospitalized with breakthrough RSV bronchiolitis, with a recurrence in three patients, one year after the initial check-up. Among patients with simple CHD, only five (1.1%) patients received one additional dose postoperatively, as per the limitations set by the Korean guideline. Among the 30 deaths (6.4%), five (1.1%) were attributed to RSV infection; three to simple CHD, one to Tetralogy of Fallot, and one to hypertrophic cardiomyopathy (HCM). Of the three HCM patients that exceeded guidelines for RSV prophylaxis, two (66.6%) were hospitalized, and one died of RSV infection (33.3%). Conclusion: In accordance to the Korean guideline, minimal injections of palivizumab were administered to patients having HS-CHD

키워드

과제정보

연구 과제 주관 기관 : Korean Pediatric Cardiology Society

참고문헌

  1. Schanzer DL, Langley JM, Tam TW. Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children. Pediatr Infect Dis J 2006;25:795-800. https://doi.org/10.1097/01.inf.0000232632.86800.8c
  2. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010;375:1545-55. https://doi.org/10.1016/S0140-6736(10)60206-1
  3. Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr 2003;143(5 Suppl):S112-7. https://doi.org/10.1067/S0022-3476(03)00508-0
  4. Altman CA, Englund JA, Demmler G, et al. Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening. Pediatr Cardiol 2000;21:433-8. https://doi.org/10.1007/s002460010103
  5. Chang RK, Chen AY. Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease. Pediatr Cardiol 2010;31:90-5. https://doi.org/10.1007/s00246-009-9577-0
  6. Cabalka AK. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease. Pediatr Infect Dis J 2004;23(1 Suppl):S41-5. https://doi.org/10.1097/01.inf.0000108220.94201.1a
  7. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-40. https://doi.org/10.1067/S0022-3476(03)00454-2
  8. Resch B, Michel-Behnke I. Respiratory syncytial virus infections in infants and children with congenital heart disease: update on the evidence of prevention with palivizumab. Curr Opin Cardiol 2013;28:85-91. https://doi.org/10.1097/HCO.0b013e32835dce2f
  9. Jung JW. Respiratory syncytial virus infection in children with congenital heart disease: global data and interim results of Korean RSV-CHD survey. Korean J Pediatr 2011;54:192-6. https://doi.org/10.3345/kjp.2011.54.5.192
  10. Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev 2013;4:CD006602.
  11. Feltes TF, Sondheimer HM, Tulloh RM, et al. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res 2011;70:186-91.
  12. Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004;114:1606-11. https://doi.org/10.1542/peds.2004-0224
  13. Meissner HC, Long SS; American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003;112(6 Pt 1):1447-52. https://doi.org/10.1542/peds.112.6.1447
  14. Shim WS, Lee JY, Song JY, et al. Respiratory syncytial virus infection cases in congenital heart disease patients. Korean J Pediatr 2010;53:380-91. https://doi.org/10.3345/kjp.2010.53.3.380
  15. Saji T, Nakazawa M, Harada K. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease. Pediatr Infect Dis J 2008;27:1108-9. https://doi.org/10.1097/INF.0b013e3181801d76
  16. Rackham OJ, Thorburn K, Kerr SJ. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations. Cardiol Young 2005;15:251-5. https://doi.org/10.1017/S1047951105000533
  17. Feltes TF, Sondheimer HM. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease. Expert Opin Biol Ther 2007;7:1471-80. https://doi.org/10.1517/14712598.7.9.1471
  18. Butt M, Symington A, Janes M, et al. Respiratory syncytial virus prophylaxis in children with cardiac disease: a retrospective singlecentre study. Cardiol Young 2014;24:337-43. https://doi.org/10.1017/S1047951113000401
  19. Medrano Lopez C, Garcia-Guereta L; CIVIC Study Group. Communityacquired respiratory infections in young children with congenital heart diseases in the palivizumab era: the Spanish 4-season civic epidemiologic study. Pediatr Infect Dis J 2010;29:1077-82. https://doi.org/10.1097/INF.0b013e3181efdac5
  20. Alexander PM, Eastaugh L, Royle J, Daley AJ, Shekerdemian LS, Penny DJ. Respiratory syncytial virus immunoprophylaxis in high-risk infants with heart disease. J Paediatr Child Health 2012;48:395-401. https://doi.org/10.1111/j.1440-1754.2011.02219.x
  21. Cohen SA, Zanni R, Cohen A, et al. Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry. Pediatr Cardiol 2008;29:382-7. https://doi.org/10.1007/s00246-007-9039-5
  22. Mitchell I, Paes BA, Li A, Lanctot KL; CARESS investigators. CARESS: the Canadian registry of palivizumab. Pediatr Infect Dis J 2011;30:651-5. https://doi.org/10.1097/INF.0b013e31821146f7
  23. Granbom E, Fernlund E, Sunnegardh J, Lundell B, Naumburg E. Evaluating national guidelines for the prophylactic treatment of respiratory syncytial virus in children with congenital heart disease. Acta Paediatr 2014;103:840-5. https://doi.org/10.1111/apa.12658
  24. Parnes C, Guillermin J, Habersang R, et al. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol 2003;35:484-9. https://doi.org/10.1002/ppul.10288
  25. Golombek SG, Berning F, Lagamma EF. Compliance with prophylaxis for respiratory syncytial virus infection in a home setting. Pediatr Infect Dis J 2004;23:318-22. https://doi.org/10.1097/00006454-200404000-00008
  26. Khongphatthanayothin A, Wong PC, Samara Y, et al. Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome. Crit Care Med 1999;27:1974-81. https://doi.org/10.1097/00003246-199909000-00042
  27. Moler FW, Khan AS, Meliones JN, Custer JR, Palmisano J, Shope TC. Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. Crit Care Med 1992;20:1406-13. https://doi.org/10.1097/00003246-199210000-00008
  28. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014;134:415-20. https://doi.org/10.1542/peds.2014-1665
  29. Chantepie A; bureau de la Filiale de Cardiologie Pediatrique de la Societe Francaise de Cardiologie. Use of palivizumab for the prevention of respiratory syncytial virus infections in children with congenital heart disease. Recommendations from the French Paediatric Cardiac Society. Arch Pediatr 2004;11:1402-5. https://doi.org/10.1016/j.arcped.2004.06.007
  30. Kristensen K, Stensballe LG, Bjerre J, et al. Risk factors for respiratory syncytial virus hospitalisation in children with heart disease. Arch Dis Child 2009;94:785-9. https://doi.org/10.1136/adc.2008.143057

피인용 문헌

  1. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection vol.13, pp.9, 2016, https://doi.org/10.1080/21645515.2017.1337614
  2. Respiratory virus prophylaxis in congenital heart disease vol.14, pp.5, 2016, https://doi.org/10.2217/fca-2017-0096
  3. Respiratory syncytial virus infection in cardiac patients: outcomes preordained by IL-6 gene polymorphism? vol.71, pp.2, 2016, https://doi.org/10.23736/s0026-4946.18.05236-2
  4. Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil vol.19, pp.1, 2019, https://doi.org/10.1186/s12887-019-1681-6
  5. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK vol.23, pp.12, 2016, https://doi.org/10.1080/13696998.2020.1836923